Table 2.

List of Protocols Opened by the Infrequent Tumor Subcommittee

Protocol No.	Protocol Name	Opening Date	Approximate No. of Institutions With IRB Approval	Proportion of Institutions With Approval (%)	Enrollment Current to December 31, 2007	Expected Accrual Current to December 31, 2007
E1697	Phase III randomized trial of 4 wk of interferon in stage T2b, T3a-b, T4a-b, T1-4 N1a, 2a melanoma	March 2004	66	30	0	—*
S0008	Phase III trial of high dose interferon versus cisplatin, vinblastine, dacarbazine, IL-2, and intrerferon in high-risk melanoma	April 2004	33	15	3	—*
ARAR0331	Treatment of childhood nasopharyngeal carcinoma with neodajuvant chemotherapy and concomitant chemoradiotherapy	February 2006	80	37	24	73
ARAR0332	Treatment of adrenocortical tumors with surgery plus lymph node dissection and multiagent chemotherapy	August 2006	50	23	7	63

Abbreviation: IRB, institutional review board.

^*No estimates were made for the Children's Oncology Group enrollment rates for E1697 and S008 but Surveillance, Epidemiology, and End Results estimates would project that approximately 20% of patients with melanoma would be eligible for one of the two melanoma trials.²²